IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v47y2024i1d10.1007_s40264-023-01367-4.html
   My bibliography  Save this article

Validation of a Natural Language Machine Learning Model for Safety Literature Surveillance

Author

Listed:
  • Jiyoon Park

    (AstraZeneca)

  • Malek Djelassi

    (AstraZeneca)

  • Daniel Chima

    (AstraZeneca)

  • Robert Hernandez

    (AstraZeneca)

  • Vladimir Poroshin

    (AstraZeneca)

  • Ana-Maria Iliescu

    (AstraZeneca)

  • Douglas Domalik

    (AstraZeneca)

  • Noel Southall

    (AstraZeneca)

Abstract

Introduction As part of routine safety surveillance, thousands of articles of potential interest are manually triaged for review by safety surveillance teams. This manual triage task is an interesting candidate for automation based on the abundance of process data available for training, the performance of natural language processing algorithms for this type of cognitive task, and the small number of safety signals that originate from literature review, resulting in its lower risk profile. However, deep learning algorithms introduce unique risks and the validation of such models for use in Good Pharmacovigilance Practice remains an open question. Objective Qualifying an automated, deep learning approach to literature surveillance for use at AstraZeneca. Methods The study is a prospective validation of a literature surveillance triage model, comparing its real-world performance with that of human surveillance teams working in parallel. The biggest risk in modifying this triage process is missing a safety signal (resulting in model false negatives) and hence model recall is the main evaluation metric considered. Results The model demonstrates consistent global performance from training through testing, with recall rates comparable to that of existing surveillance teams. The model is accepted for use specifically for those products where non-inferiority to the manual process is rigorously demonstrated. Conclusion Characterizing model performance prospectively, under real-world conditions, allows us to thoroughly examine model consistency and failure modes, qualifying it for use in our surveillance processes. We also identify potential future improvements and recognize the opportunity for the community to collaborate on this shared task.

Suggested Citation

  • Jiyoon Park & Malek Djelassi & Daniel Chima & Robert Hernandez & Vladimir Poroshin & Ana-Maria Iliescu & Douglas Domalik & Noel Southall, 2024. "Validation of a Natural Language Machine Learning Model for Safety Literature Surveillance," Drug Safety, Springer, vol. 47(1), pages 71-80, January.
  • Handle: RePEc:spr:drugsa:v:47:y:2024:i:1:d:10.1007_s40264-023-01367-4
    DOI: 10.1007/s40264-023-01367-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-023-01367-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-023-01367-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kristof Huysentruyt & Oeystein Kjoersvik & Pawel Dobracki & Elizabeth Savage & Ellen Mishalov & Mark Cherry & Eileen Leonard & Robert Taylor & Bhavin Patel & Danielle Abatemarco, 2021. "Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices," Drug Safety, Springer, vol. 44(3), pages 261-272, March.
    2. Karolina Danysz & Salvatore Cicirello & Edward Mingle & Bruno Assuncao & Niki Tetarenko & Ruta Mockute & Danielle Abatemarco & Mark Widdowson & Sameen Desai, 2019. "Artificial Intelligence and the Future of the Drug Safety Professional," Drug Safety, Springer, vol. 42(4), pages 491-497, April.
    3. Robert Ball & Gerald Dal Pan, 2022. "“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?," Drug Safety, Springer, vol. 45(5), pages 429-438, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Oeystein Kjoersvik & Andrew Bate, 2022. "Black Swan Events and Intelligent Automation for Routine Safety Surveillance," Drug Safety, Springer, vol. 45(5), pages 419-427, May.
    2. Andrew Bate & Steve F. Hobbiger, 2021. "Artificial Intelligence, Real-World Automation and the Safety of Medicines," Drug Safety, Springer, vol. 44(2), pages 125-132, February.
    3. Ghobakhloo, Morteza & Asadi, Shahla & Iranmanesh, Mohammad & Foroughi, Behzad & Mubarak, Muhammad Faraz & Yadegaridehkordi, Elaheh, 2023. "Intelligent automation implementation and corporate sustainability performance: The enabling role of corporate social responsibility strategy," Technology in Society, Elsevier, vol. 74(C).
    4. Kristof Huysentruyt & Oeystein Kjoersvik & Pawel Dobracki & Elizabeth Savage & Ellen Mishalov & Mark Cherry & Eileen Leonard & Robert Taylor & Bhavin Patel & Danielle Abatemarco, 2021. "Validating Intelligent Automation Systems in Pharmacovigilance: Insights from Good Manufacturing Practices," Drug Safety, Springer, vol. 44(3), pages 261-272, March.
    5. Saha, Krishnendu & Okmen, Nimet, 2025. "Artificial Intelligence in Pharmacovigilance: Leadership for Ethical AI Integration and Human-AI Collaboration in the Pharmaceutical Industry," CAFE Working Papers 34, Centre for Accountancy, Finance and Economics (CAFE), Birmingham City Business School, Birmingham City University.
    6. Barenji, Reza Vatankhah & Hariry, Reza Ebrahimi & Demirkol, Denizhan & Daim, Tugrul U., 2024. "Research landscape analysis for quality in Pharma 4.0 era," Technology in Society, Elsevier, vol. 76(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:47:y:2024:i:1:d:10.1007_s40264-023-01367-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.